Board of directors

The following members were elected to the Board of Directors at the Extraordinary General Meeting 2017, which occurred on July 21, 2017

Kirk Gorman
(Chairman, newly elected)
Kirk Gorman

Mr. Gorman was appointed to serve as TJU’s and JHS’s Executive Vice President and Chief Financial Officer in October 2014. Prior to joining TJU and JHS, Mr. Gorman had been the Executive Vice President and Chief Financial Officer of Jefferson Health System and Universal Health Services, Inc. since 2003 and 1987 respectively, and President of Universal Health Realty Income Trust from 1987 to 2003. Mr. Gorman is a member of the Boards of BioTelemetry, Inc. and IASIS Healthcare. Mr. Gorman has served on the Boards of Physician’s Dialysis Inc., HCF Guernsey Ltd., VIASYS Healthcare Inc. and Care Investment Trust. Prior to Universal, he was at Mellon Bank for thirteen years, where he served as a senior vice president. Mr. Gorman holds an MBA from the Amos Tuck School of Business at Dartmouth College, where he also received his undergraduate degree.

Joseph H. Capper
(newly elected)
Joseph H. Capper

Joe Capper was appointed President and Chief Executive Officer of CardioNet in June 2010 and now serves in that same capacity for BioTelemetry. Prior to CardioNet, Joe served as President, Chief Executive Officer and member of the Board of Directors of Home Diagnostics, Inc., a leading developer, manufacturer and marketer of diabetes management products. Joe joined Home Diagnostics in 2009 and positioned the Company for a strategic merger in a transaction that created substantial value to its stakeholders. Home Diagnostics was listed on the NASDAQ stock market until its strategic merger.

Prior to Home Diagnostics, Joe was President and Chief Executive Officer of CCS Medical Inc., a private company that is a leading provider of medical supplies in diabetes, wound care, respiratory and other therapeutic categories. During Joe’s tenure as Chief Executive Officer, he built the Company into one of the largest providers of diabetes and respiratory testing supplies for Medicare beneficiaries and the private insured. During this time, the Company’s revenue grew from $60 million to over $500 million through organic growth and acquisitions.

Earlier in his career, Joe spent nine years with Bayer Corporation, ultimately becoming National Sales Director of the Diabetic Products Division where he led a 180-person sales organization with responsibility for over $350 million in revenue. Joe also has a distinguished service record having served in the U.S. Navy as a combat aviator and subsequently as a Congressional Liaison. Joe received his undergraduate degree in Accounting from West Chester University and an MBA in International Finance from George Washington University.

Dr. Stephan Rietiker
(newly elected)
Dr. Stephan Rietiker

Dr. Stephan Rietiker, a dual citizen of both Switzerland and the United States, received his medical doctorate from the University of Zurich in 1982 and also qualified to practice medicine in the United States. He spent five years practicing internal medicine before moving into the Healthcare industry. Dr. Rietiker began his career with Roche in 1987 and thereafter held several senior positions in marketing / general management with Boehringer Mannheim and Schering Plough. Subsequently, he became Vice President and General Manager Europe for Covance Central Laboratory Services. In 2001, he was appointed President and CEO of Sulzer Medica (later Centerpulse) and was instrumental in resolving a landmark legal settlement in a major U.S. litigation. He was also responsible for restructuring the company which ultimately led to its acquisition by Zimmer in 2003. After a year as CEO and Director at Pendragon Medical AG, he took on the role of Executive Director and CEO at IMI Intelligent Medical Implants in 2004. In 2006, Dr. Rietiker left IMI and incorporated AurigaVision AG, a Switzerland based investment platform that focuses on promising developmental-stage healthcare companies. This activity led to his involvement with LifeWatch AG where he initially served as Executive Board Member and Interim CEO. After four months, he permanently was appointed CEO of LifeWatch AG, a position he still holds today. Dr. Rietiker also served as a Senior Advisor to Brown Brothers Harriman’s Corporate Finance team from 2006 – 2014. And, since 2014, Dr. Rietiker has been serving on the Board of Directors for California-based LoneStar Heart, a company developing breakthrough therapies against advanced heart failure.